Skip to main content Accessibility help
×
Home
Hostname: page-component-564cf476b6-scc96 Total loading time: 0.175 Render date: 2021-06-19T15:55:44.031Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true }

Canadian Consensus Conference on Dementia: Two Years Later

Published online by Cambridge University Press:  02 December 2014

Rights & Permissions[Opens in a new window]

Abstract

Image of the first page of this article. For PDF version, please use the ‘Save PDF’ preceeding this image.
Type
Other
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

1. Petersen, RC, Smith, GE, Waring, SC. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol. 1999; 56: 303308.CrossRefGoogle ScholarPubMed
2. Ritchie, K, Touchon, J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet 2000; 355: 225228.CrossRefGoogle ScholarPubMed
3. Blacker, D, Tanzi, RE. The genetics of Alzheimer disease. Arch Neurol 1998; 55: 294296.CrossRefGoogle ScholarPubMed
4. Munoz, DG, Feldman, H. Causes of Alzheimer’s disease. CMAJ 2000; 162: 6572 Google ScholarPubMed
5. Corey-Bloom, J, Anand, R, Vach, J for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatric Psychopharmacol 1998; 1: 5565.Google Scholar
6. Rosler, M, Anand, R, Cicin-Sain, A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s Disease: international randomised controlled trial. Br Med J 1999; 318 (7184):633638.CrossRefGoogle ScholarPubMed
7. Raskind, MA, Peskind, ER, Wessel, T, Yuan, W, and the Galantamine USA-1 Study Group. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 22612268.Google ScholarPubMed
6. Tariot, PN, Solomon, PR, Morris, JC, Kershaw, P, Lilienfeld, S, Ding, C, and the Galantamine USA-10 Study Group. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 22692276.CrossRefGoogle ScholarPubMed
9. Feldman, H, Gauthier, S, Hecker, J, Vellas, B, Subbiah, P, Whalen, E, and the Donepezil MSAD Study Group. Benefits of donepezil on global function, behaviour, cognition, and ADLs in patients with moderate-to-severe Alzheimer’s disease. Neurology 2000; 54(3); A469.Google Scholar
10. Shea, C, Macknight, C, Rockwood, K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patient. Int Psychogeriatr 1998; 10(3): 229238.CrossRefGoogle Scholar
11. De Deyn, PP, Rabheru, K, Rasmussen, A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 1999; 53:946955.CrossRefGoogle Scholar
12. Katz, IR, Jeste, DV, Mintzer, JE, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999; 60:107115.CrossRefGoogle Scholar
13. Defilippi, JL, Crismon, ML. Antipsychotic agents in patients with dementia. Pharmacotherapy 2000; 20(S1): 2333.CrossRefGoogle ScholarPubMed
You have Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Canadian Consensus Conference on Dementia: Two Years Later
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Canadian Consensus Conference on Dementia: Two Years Later
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Canadian Consensus Conference on Dementia: Two Years Later
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *